|Numéro de publication||WO1995015493 A1|
|Type de publication||Demande|
|Numéro de demande||PCT/US1994/012623|
|Date de publication||8 juin 1995|
|Date de dépôt||2 nov. 1994|
|Date de priorité||2 nov. 1993|
|Numéro de publication||PCT/1994/12623, PCT/US/1994/012623, PCT/US/1994/12623, PCT/US/94/012623, PCT/US/94/12623, PCT/US1994/012623, PCT/US1994/12623, PCT/US1994012623, PCT/US199412623, PCT/US94/012623, PCT/US94/12623, PCT/US94012623, PCT/US9412623, WO 1995/015493 A1, WO 1995015493 A1, WO 1995015493A1, WO 9515493 A1, WO 9515493A1, WO-A1-1995015493, WO-A1-9515493, WO1995/015493A1, WO1995015493 A1, WO1995015493A1, WO9515493 A1, WO9515493A1|
|Inventeurs||Richard A. Quattrocchi|
|Déposant||Anonymous Test Services, Inc.|
|Exporter la citation||BiBTeX, EndNote, RefMan|
|Citations de brevets (5), Citations hors brevets (2), Référencé par (8), Classifications (7), Événements juridiques (5)|
|Liens externes: Patentscope, Espacenet|
METHOD AND SYSTEM FOR ANONYMOUSLY TESTING FOR A HUMAN MALADY
FIELD OF THE INVENTION
The present invention relates to a method and system for testing for human malady and, more paπicularly, to a method and system for testing for the Human Immunodeficiency Virus (HIV) which is responsible for Acquired Immune Deficiency Syndrome (AIDS). BACKGROUND OF THE INVENTION
Many of today's human maladies are highly contagious, readily transmissible, and, in some cases, medical cures have not yet been discovered. For example. AIDS has become a serious health threat and has reached epidemic proportions around the world. Presently, there is no cure for AIDS or for the HIV virus that causes AIDS. While having the HIV virus does not necessarily mean that a person will contract AIDS, because of its contagiousness and transmissibility, it is important to know whether a person is infected with the HTV virus.
Both HTV and AIDS are not inherited but are acquired. HIV is passed from one person to another as through the transference body fluid such as infected blood, semen or vaginal fluids. Accordingly, HTV is often transmitted by unprotected vaginal, anal, or oral sexual intercourse, or through the sharing of hypodermic needles by intravenous drug users. Infants can also acquire HIV from their mothers during pregnancy or delivery.
A fundamental step in preventing the spread of HIV and AIDS is to inform those people who are infected about their condition. Hopefully, once someone knows they are O 95/15493
infected they will take extra precaution in their activities thereby containing the spread of the disease. While a cure for the HIV and AIDS has not yet been found, the medical community has developed accurate tests to detect the presence of HIV antibodies in the
blood stream. The most recognized tests are known as the Enzyme Linked Immunosorbent Assay (ELISA) and the Western Blot tests. By combining these highly effective tests, test results can be approximately 99.7 percent accurate.
HIV antibodies develop in the blood stream after someone is infected with HIV. These antibodies can take up to six (6) months to develop before being detected by d e ELISA and Western Blot tests. Accordingly, immediate infection with HIV virus is not necessarily detectable.
Even though the tests for HIV are highly accurate, many people are reluctant to have themselves tested. A fundamental reason for this reluctance is fear: The fear of death and the stigma of having AIDS. Not only do people with AIDS have to deal with this devastating and terminal disease, but they also have to combat other people's prejudices and fear.
The general populace's prejudice and fear stem from many different things. One reason is general discrimination towards homosexual men. The homosexual male population was one of the first communities heavily affected by AIDS. Accordingly, AIDS became known as a gay disease and people with AIDS are assumed to be gay.
A deeper element to the problem is based in the public's general lack of understanding about how one can contract the HIV virus. Casual contact does not promote the spread of the disease. However, until the public understands this, people with AIDS tend to be ostracized from their community at a time when they need the most support. Adults have been fired from their jobs, and children have been locked out of their schools.
Problems for people with HIV and AIDS has also presented itself in the medical community. People with HIV and AIDS can find it hard to find a doctor that will treat them, and quite often insurance companies are unwilling to pay for the necessary and expensive treatments that AIDS patients often require.
Taking into account these factors, the decision to take an HIV antibody test is a
difficult choice to make. However, there are many good reasons to do so, such as: A
need to know; anxiety relief; protecting oneself; protecting one's sexual partners; protecting one's children; and obtaining early medical intervention.
However, people are still afraid to take a test for the fear that others will find out if the test is positive. There are procedures to ensure that one's HIV status is protected from others. There is no system or method, however, that completely protects the identity of the person who has submitted a blood sample to be tested.
In the past, systems have been developed that attempt to protect individuals from the general dissemination of test results. Medical practices and policies, like the doctor- patient privilege, attempt to protect people with AIDS. There are clinics which have procedures for anonymous testing. These clinics use number identifiers to protect patient confidentiality. However, the patient must appear at the clinic where he or she could be recognized by anyone else at the clinic. Accordingly, complete anonymity is difficult to maintain.
Tests have been developed and marketed that allow people to take a blood sample at home and mail it to a medical laboratory for analysis, e.g., Briggs et al. United States Patent Nos. 4,777,964 and 4,979,515. These tests offer anonymity because the user does not appear at a laboratory, hospital or doctor's office. These tests, however, do require the person taking the test to give the laboratory his or her name and address. Thus, total anonymity for the person being tested is lost thereby discouraging people from taking the test.
Furthermore, the previous personal testing kits have only required the user to supply one blood sample. While often this is sufficient for accurate results, sometimes more than one blood sample is required because multiple tests are needed. It is important to make sure that the results to HIV antibody tests are accurate because of the severe consequences, e.g. death and discrimination, of a positive result.
Accordingly, a medical testing system is needed that is particularly designed to test for the HIV virus and allow the user to be completely anonymous. The test should also supply the medical lab with enough blood samples to ensure that the test result is as accurate as possible. The presently described invention addresses these mentioned needs. SUMMARY OF THE INVENTION
In view of the above, and in accordance with the present invention, there is provided a method and system of testing for a human malady in private. One such human malady would be HIV. The test is privately conducted and d e test results are anonymously reported to the person taking the test without revealing his or her identity. The method includes the steps of procuring a kit that is capable of taking a suitable test specimen from the person being tested. The kit has a unique personal code associated with it and all the necessary equipment for the person taking the test to be able to obtain the test specimen in private. The person taking the test proceeds by creating or activating a personal electronic file through a telephone operated software program. The electronic file that is set up is identified by the personal code assigned to the kit. The electronic file is a data file for demographic information about the individual. At this time, the person taking the test can also be offered pretest counseling regarding the test and the test results.
The method continues with the person taking the test using the equipment provided in the kit to obtain the test specimen. In the situation where the person taking the test is
concerned about AIDS, the test specimen is a blood sample. Once there is a test
specimen, the next step is sending the test specimen for analyzation; the test specimen is sent with only the personal code to identify the person taking the test.
After the specimen is sent and d e personal electronic file is created, the next step is analyzing the sample to obtain results. In the situation where the person taking the test is concerned about HIV, the ELISA and Western Blot methods to determine if the HIV antibodies are present in the test specimen. Other tests can be performed on the test specimen to detect a variety of diseases. Once the analyzation step is completed, d e electronic file identified by the personal code that corresponds to the personal code of d e test specimen is updated by adding d e results.
After a sufficient period of time for analyzation and adding d e results to the personal electronic file has elapsed, the next step is telephonically accessing die test results in the personal electronic file through the telephone operated software program using the personal code, thereby maintaining anonymity.
Depending on die results of the test, the telephone operated software proceeds by sending the person to d e appropriate source to receive d e results. If the test results show the presence of a human malady, die person taking die test is told the results and counseled by a counselor who does not know die identity of the person. On the other hand, if the test results show no human malady, die individual is told by the telephone
operated software program and is encouraged to speak to a counselor if there is any reason to do so.
The test system herein permits anonymous testing for a particular human malady, and die system includes a kit having die necessary equipment for producing a suitable test specimen from a person being tested which is capable of being transported from one location to another location for analyzation. The kit allows the specimen to be collected in private. To maintain anonymity, a personal code identifies d e person being tested and the test specimen. An electronic file is created and accessible by die person being tested and is identified by die same personal code. The electronic file has entered into it the results of the analysis after the test specimen is analyzed.
As mentioned above, d e test kit is equipped wid all d e proper equipment that an individual will need to acquire a test specimen. When the kit is used to test for HIV, the equipment will obtain a blood sample mat is sufficient to analyze for HIV antibodies using the ELISA med od and die Western Blot method. The kit comes equipped widi an alcohol swab to clean an area of the skin, preferable the tip of die middle or ring finger, before the blood sample is taken, and at least two lancets diat can puncture the skin so that blood can be acquired. A sterile gauze pad is provided to clean away the first drop of blood which is not suitable for the blood sample. The blood sample is produced by placing enough blood on a specially designed blood specimen collection card provided in the kit to fill preferably four specimen spots. The collection card is preferably configured as a iree part card. The first part of the card has printed thereon the personal code and a telephone number that is used by d e person being tested to create the personal electronic file. The second part is an informed consent form with an area to be anonymously filled in by the person being tested widi the personal code. The d ird part is special paper with specimen spots outlined d ereon for the person being tested to create specimens for testing. The test kit further includes at least one bandage to protect the puncture after the blood sample is produced.
To send die kit to the medical lab, die kit is supplied with a foil lined envelope
where the individual inserts the collection card and a drying agent. The foiled lined envelope is placed in a specially marked specimen bag mat is also sealed. The waste is placed in another specially marked waste bag that is also sealed. The specimen bag and the waste bag are placed in a container, which is then placed in a mailing envelope and sent for analyzation and disposal, respectively. Alternatively, die waste can be disposed of locally.
These and numerous other objects, aims and advantages of die present invention will become readily apparent from the following detailed description, appended claims, and die accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 depicts d e outer box that holds d e contents of the medical testing equipment of the presently disclosed invention:
FIGURE 2 illustrates the box of FIGURE 1 in its open state with an exploded view of the testing equipment; FIGURE 3 illustrates the sealed bag and die enclosed equipment in block form of the present invention;
FIGURE 4A & 4B are detailed drawings of the blood specimen collection card;
FIGURE 5 is a flow chart showing the steps a user takes to obtain a blood specimen;
FIGURE 6 A & 6B illustrate the elements of the electronic file; and
FIGURE 7 is a flow chart showing die operation of the telephone operated automated software associated widi die present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
While the present invention is susceptible of embodiment in various forms, there is shown in the drawings and will hereinafter be described a preferred embodiment of die invention wid die understanding d at the present disclosure is to be considered as setting forth an exemplification of the invention which is not intended to limit the invention to die specific embodiment illustrated.
Referring now to the drawings, wherein like reference numerals indicate like parts throughout die several views, the present invention is an anonymous testing system which utilizes a kit 10 as a primary component thereof. As shown in FIGURE 1, kit 10 includes an outer box 12 used to package and mail die kit 10. Multiple tabs 14 inserted into multiple slots 16 are provided to keep die box 12 in its folded and secure position as shown in FIGURE 1. FIGURE 2 illustrates how when tabs 14 are removed from slots 16 box 12 can be unfolded to reveal the enclosed equipment which are used for die anonymous medical test. All equipment in the medical test comes confined in a vacuum sealed clear plastic bag 18 as shown in FIGURE 3. The clear plastic bag allows the person being tested to examine the contents of the test to determine if all the necessary parts are provided.
The necessary components for the test are also revealed in FIGURES 2 and 3. The equipment preferably includes: 1) an alcohol swab 20; 2) at least two lancets 22; 3) a gauze pad 24; 4) a blood specimen collection card 26; 5) at least two bandages 28; 6) a drying agent (desiccant) 30; 7) a storage packet 32; 8) a specimen bag 34, and 9) a waste bag 36. A mailing envelope 38 may also be provided widi die kit 10 to facilitate
returning a test specimen for analyzation. ,
Alcohol swab 20 is preferably a 1 1/4 inch by 2 5/8 inch single fold, nonwoven applicator swab saturated widi 70% isopropyl alcohol. To prolong the usefulness, swab 20 is preferably packaged in a foil tear-open packet, and can be of die type produced by Baxter Healdicare Corporation. Alcohol swab 20 is used to clean an area of skin from which blood will be drawn.
Lancets 22 are preferably single use lancets widi a blade widd of 1.0 mm and blade depth of 2.2 mm such as Becton Dickinson Microtainer Brand "Yellow" Safety Flow Lancets. Lancets 22 are used to puncture the cleaned skin of the user.
Gauze pad 24 is preferably a 2 inch by 2 inch sterile 12-ply sponge pad of 100% cotton USP Type VII gauze like that manufactured by Johnson & Johnson. Gauze pad 24 is used to clean and dry the skin around the puncture area.
The bandages 28 provided are preferably 1 inch by 3 inch sterile wrapped adhesive strips of the type manufactured by Johnson & Johnson as Band- Aid® brand bandages. The bandages 28 are used to cover the punctured skin after blood samples are taken. The drying agent 30 can be any desiccant, but is preferably a silica gel like the one produced by U.D.G of Belen, New Mexico and marketed as Sorb-It®.
FIGURES 4A and 4B illustrates the blood specimen collection card 26 which is preferably a 4 1/2 inch by 3 1/2 inch diagnostic form having three (3) parts. The first part is a removable top sheet 40. Perforations 42 are preferably provided to enable die person being tested to remove the top sheet 40 from the remainder of the collection card 26. Printed on top sheet 40 is information that the person being tested needs to retain after the remainder of the collection card is sent for analysis. This information includes a personal code 44 and a phone number 46.
Personal code 44 is used to identify die blood specimen and d e person being tested rather than a name and/or address. The personal code 44 is a randomly assigned number to the kit 10 so diat each kit has a unique code 44 associated dierewith. Because each number is unique, the person being tested can remain completely anonymous while having his or her blood specimen analyzed. As shown in FIGURE 4A, the personal code 44 is preferably an eleven (11) digit number. Nine digits, indicated by "0"s, are randomly assigned and the remaining two digits, indicated by "X"s, are used as a check sum to assure accuracy each time the number is used. It should be noted that any odier system of identification can be used as long as d e indicators are randomly assigned to each kit 10. The telephone number 46 allows the user to access the telephone operated software program 48 to generate a personal electronic file 50 and to access the results of the test, which will be discussed below.
The second part of collection card 26 is an informed consent form 52. The informed consent form 52 contains a series of statements that the person being tested must read, understand, and acknowledge before a laboratory can perform any test on the specimen. The informed consent form 52 is returned along widi die specimen. The consent form 52 has a space 54 which the individual fills in thereby acknowledging having read and understood die statements. To keep the anonymity of me person being tested, the user fills in the space 54 widi die personal code 44.
The dύrd part of collection card 26 is a blood specimen sample sheet 56. Sample sheet 56 is made of at least in part a cotton fiber filter paper preferably like that manufactured by Schleicher and Schuell® as #903™. Sample sheet 56 has similarly shaped
sections 58 outlined d ereon. In the preferred embodiment, four sections 58 are used so that d e individual will provide at least four specimens for analyzation. The sections 58 are outlined using black biological ink so that die ink will not interfere with the specimen and an accurate test result can be obtained. It is best if die shapes are circles of approximately 0.375 inches in diameter. The sections 58 are spaced adequately apart so that die four different specimens will not be commingled and diat acquiring the specimens will not be too difficult. Also placed on die sample sheet is a bar code 60 that has die same personal code 44 as was randomly assigned to die top sheet 40. The bar code 60 is used by the laboratory to identify die specimen as belonging to die person being tested who has been assigned die corresponding personal code 44. Accordingly, d e person being tested and assigned d e personal code 44 can be updated widi die results of the analyzation.
Storage packet 32 is opaque and is preferably a foil lined envelope. As shown in FIGURE 2, the top edge 62 has an adhesive strip 64 covered by removable silicon strip. The dimensions of storage packet 32 are large enough to hold the collection card 26. After the test specimen has been completed, it is inserted widiin the storage packet 32 along with d e drying agent 30.
After the collection card 26 and drying agent 30 are deposited widiin d e storage packet, the silicon strip is removed from the adhesive strip 64 and d e top edge 62 is folded down so that die adhesive strip 64 sticks to the outside of the storage bag 32 thereby sealing the storage packet 32 closed. Specimen bag 34 is a clear plastic bag that can be securely sealed along its upper edge and is large enough to hold die storage packet 32. On the outside surface of the specimen bag 34, there is a label 66 preferably stating "specimen" so mat d e purpose and contents of die bag are clearly stated. The waste bag 36 is also a clear plastic bag that can be securely sealed along its upper edge. Waste bag 36 also preferably has a label 68 stating "Caution Biohazard" along with d e typical biohazard symbol so mat die contents of the bag 36 are readily identified as medical waste. The waste bag is large enough to hold the remaining and used elements of the test system 10, e.g. me lancets 22 and gauze 24.
Mailing envelope 38 is preferably a typical express mail type envelope used by e.g. , Federal Express® or the United States Postal Service.® The mailing envelope 38 should be sufficiently large enough to hold die box 12 dierein for sending to die laboratory.
FIGURE 5 illustrates the use of die kit 10 and d e equipment described above. To begin, the user opens up the box to reveal the testing equipment (See FIGURES 1 and 2). The kit 10 can also contain an instruction booklet (not shown) which serves to help the person being tested obtain a specimen and answer any questions. Initially, the person being tested should activate the personal code 44 assigned to the kit 10 using the telephone automated software program 48. The user will find die assigned code 44 on die top sheet 40 of the collection card 26. Also on the top sheet 40 is the telephone number 46 the person being tested calls to activate die personal code 44. By using the push buttons of the telephone, die user registers the code 44 at a central location. If the user does not have a touch tone telephone, a counselor will be provided to activate the personal code 44.
When d e person being tested telephones to activate d e personal code 44, the
telephone automated software program 48 collects demographic information, and the
person being tested is preferably offered pre-test counseling. The demographic information will not include any information that would divulge die true identity of die person being tested. The type of information sought concerns the sex and age of die person being tested, and the person's zip code and is inserted into a database electronic file 50 as depicted in FIGURE 6. Organizations like a local health department the Center for Disease Control in Atlanta, Georgia can then use diis information for statistical purposes in its monitoring of the AIDS epidemic.
The pre-test counseling is an opportunity for the central location to help the person being tested cope widi die possibility diat d e results from the test will be positive. A counselor will ask a series of questions like, "What do you expect your test results to be?" "What would you do if your test results are positive?" "Who could you rely on for support if your test results are positive?" etc.
The person being tested must also acknowledge that he or she has read and understood the informed consent form 52 on the collection card 26. The informed consent form 52 has a series of statements informing the user about the test, the meaning of the results, and audiorizing a medical laboratory to test the blood specimen sent to it for the presence of HIV antibodies. In order to protect anonymity, the person being tested is reminded to fill in die consent form 52 with the assigned personal code 44 rather than sign his or her name. The consent form 52 should not be removed from the collection card 26.
The person being tested dien selects and cleans a skin area with soap and water. To assure cleanliness, die alcohol swab 20 is preferably used to further clean an area. The skin area can be from any part of the body, but d e tip of the middle or ring finger is preferable. After the fmger is cleaned, d e person being tested should dry the finger tip with die sterile gauze pad 24.
The person being tested opens one of d e two lancets 22 provided which will be used to puncture die cleaned area thereby producing a flow of blood. In order to effectively use the lancet 22, die person being tested should stabilize the finger such as on a flat hard surface and position die lancet 22 between die fore and middle fingers of the opposite hand. The lancet 22 is dien placed against the pad of d e finger tip thereby causing a dimple. When me person being tested is ready, die lancet's plunger is depressed and held for a split-second. This motion causes die blade of die lancet to puncture the skin thereby producing a flow of blood. After the puncture is created, die lancet is removed from the finger area, and die first drop of blood is wiped away by die sterile gauze pad 24. Anodier drop of blood should develop soon diereafter.
Next, the person being tested applies die drops of blood developing on d e finger tip to the sample sheet 56 of the collection card 26 by gently touching the finger to each of the separate specimen sections 58 after a large drop of blood has developed. The person being tested should keep die sample sheet 56 in contact with die finger to allow a sufficient quantity of blood to soak dirough sample sheet 56 and fill die specimen sections 58. Each of the specimen sections 58 provided should be filled in a similar fashion.
If the person being tested has problems producing enough blood from the puncture to fill each specimen section 58, die person can use another lancet 22 to create a second puncture area on the finger thereby causing blood to flow from a different spot. The
second lancet should be used because of d e problem using the first one again. The
lancets 22 are designed for single use and attempting to use a lancet 22 twice might not produce a flow of blood.
After all the specimen sections 58 are completely filled, the person being tested can bandage the area puncture with one of die bandages 28 d at is provided.
Once die person being tested has acquired d e necessary blood sample on die collection card 26, the collection card 26 and waste is preferably prepared for sending away where they will be analyzed and disposed of, respectively. Alternately, the waste can be disposed of locally. The drying agent 30 is inserted into the storage packet 32 and followed by d e collection card 26. The silicon strip is removed, and die top edge 62 of die storage package 32 is folded over so that the adhesive strip 64 sticks to the outside surface of the storage packet 32 thereby sealing the collection card into the storage bag 32. After the storage packet 32 is sealed, die person being tested inserts it into the specimen bag 34, which is sealed at its top edge. The person being tested then places the remaining equipment into the waste bag 36. The items to be placed into the waste bag 36 preferably include the used alcohol
swab 20, d e lancets 22 provided, regardless if they have been used or not, the used gauze pad 24, and die remaining bandages 28 along widi any wrappers or packaging. The only thing diat ought to remain outside eid er the specimen bag 34 or the waste bag 36 should be die top sheet 40 which die user needs for future reference.
The person being tested dien takes the specimen bag 34 and the waste bag 36 and puts diem into die box 12. The flaps 14 are inserted into the slots 16 so that die box is secured shut. Then, the person places the box 14 into the mailing envelope 38 so diat die medical lab can receive the collection card 26 and the waste for testing and disposal, respectively.
After the blood sample has been sent to me laboratory for testing, the user should wait a number of days before analysis can be performed on die specimen and the results relayed to die user. When the laboratory receives the collection card 26, it will perform the ELISA test to detect for HIV antibodies. If die ELISA test is positive, die Western Blot test will be performed to confirm a positive result. When the results of the test are known, die laboratory will update die electronic file 50 set up by the person being tested diat corresponds to die bar code 60. After the electronic file 50 is updated, die person can access the test results. It should take approximately seventy-two hours after die laboratory has received die collection card 26 to update the electronic file 50.
In order to obtain die test results, the person will call the phone number 46, which can be found on the retained top sheet 40. If the test results are negative, the telephone- operated computer software program 48 will so inform the user. On the other hand, a counselor will inform me user of the positive results. This way the user can be told how to get the proper medical attention and to determine if the user has possibly infected others with the HIV virus. At no point in the process is the identity of the user revealed. Also if die test results are positive, the local heald department and/or the Center for Disease Control can be informed.
FIGURE 6A & 6B illustrates the elements of the personal electronic file 50 that is created by the person being tested when he or she telephones the telephone automated computer program 48 to activate the personal code 44 assigned to d e kit 10. The
electronic file 50 is a computer database file d at holds all d e relevant non-identifying data about die person being tested. The electronic file 50 has at least two area; a patient record 70 and a call log 72. The patient record holds relevant information about the person such as the personal code 44, the sex, birth date, zip code, whedier the person has been tested before, and test result. A call log 72 is set up for each time mat die user calls. Each call log 72 is identified by the users personal code 44, and also designates die date and time of each call. There is also space for a counselor to put notes about each call.
The telephone automated software program 48 has been developed for people to set up and access ti eir electronic files 60. When a person calls the telephone number 46, the person first accesses the telephone automated software program 48. FIGURE 7 is a flow chart illustrated die steps of the telephone automated software program 48. The program 48 preferably begins by asking if the user is calling to set up his or her electronic file 50, or calling to receive test results. (Step 1). The person being tested selects the appropriate number on the push button telephone depending on the response to step one. If die person does not have a touch tone telephone, a counselor will answer the phone and proceed in collecting the relevant information.
If the person is calling to set up die electronic file, the program 48 asks die user to enter the eleven digit personal code 44. (Step 2). After the number is entered, die program 48 repeats the entered number. (Step 3). If the number repeated is incorrect, Step 2 is repeated, odierwise the program 48 proceeds by asking die person to complete the electronic file 50. (Step 4). After the electronic file 50 is completed, me program 48 connects the user to a counselor for pre-test counseling. (Step 5).
On the other hand, if the person being tested is calling to get results, the program 48 begins by asking the person to enter the eleven digit personal code 44. (Step 6). After the number is entered, die program 48 repeats the entered number. (Step 7). If the number repeated is incorrect, Step 6 is repeated, odierwise the program 48 proceeds so diat the person will receive the test result. If the test results are negative, the program 48 so informs the person. (Step 8). Step 8 also encourages the user to talk to a counselor and to take the test again if there is any reason to believe that HIV antibodies will develop in die future. (Step 9)
If the test results are positive, the program 48 transfers the user to a counselor to inform the user of the results. (Step 10). Step 10 further takes the opportunity to counsel the person being tested about how to get proper medical attention, face-to-face counseling and to determine if mere are any people that die user should inform about the test results because they might also be infected widi die HIV virus.
It should be noted diat the principles of an anonymous testing procedure as disclosed herein can be used for other diseases where the user does not want his or her name disclosed. Furthermore, the procedure does not have to be limited to testing for diseases, but can be used in odier fields.
From the foregoing, it will be observed diat numerous modifications and variations can be effected wi out departing from the true spirit and scope of d e novel concept of die present invention. It will be appreciated that the present disclosure is intended as an exemplification of me invention, and is not intended to limit the invention to the specific embodiment illustrated. The disclosure is intended to cover by the appended claims all
such modifications as fall widiin the scope of the claims.
|Brevet cité||Date de dépôt||Date de publication||Déposant||Titre|
|US3883396 *||30 mars 1973||13 mai 1975||Jr Charles A Thomas||Gonorrhea detecting|
|US4277249 *||15 oct. 1979||7 juil. 1981||Nichols Institute||Mammalian Somatomedin measurement|
|US4777964 *||20 mai 1987||18 oct. 1988||David Briggs||System for obtaining blood samples and submitting for testing of aids|
|US4792968 *||24 févr. 1987||20 déc. 1988||Fdr Interactive Technologies||Statistical analysis system for use with public communication facility|
|US5156948 *||20 juil. 1990||20 oct. 1992||Christensen Dale A||Method and kit for diagnosis of diseases|
|1||*||AMERICAN JOURNAL OF HOSPITAL PHARMACY, Volume 47, Number 3, issued March 1990, DECHRISTOFORO, "What is the Status of AIDS Antibody Home Test Kits?", page 619.|
|2||*||NATURE, Volume 332, issued 14 April 1988, ANDERSON, "Home Test Kits for AIDS Blocked", page 573.|
|Brevet citant||Date de dépôt||Date de publication||Déposant||Titre|
|WO2001070023A1 *||26 févr. 2001||27 sept. 2001||Jan Jaap Nietfeld||Method for anonymously registering, storing and using body material and/or information derived therefrom|
|WO2003063048A2 *||21 janv. 2003||31 juil. 2003||Genonyme Gmbh||Method and system for the analysis of medical and personal data|
|WO2003063048A3 *||21 janv. 2003||18 nov. 2004||Uwe Bicker||Method and system for the analysis of medical and personal data|
|WO2015183150A1 *||19 mars 2015||3 déc. 2015||Bodymarkers Ab||A method and a system for performing a health test|
|WO2016007064A1 *||19 mars 2015||14 janv. 2016||Bodymarkers Ab||A method and a system for performing a health test of an animal|
|US6867016 *||31 mars 1998||15 mars 2005||Abbott Laboratories||Reagents and methods useful for detecting diseases of the gastrointestinal tract|
|US7706983||26 févr. 2001||27 avr. 2010||Intresco B.V.||Method for anonymously registering, storing and using body material and/or information derived therefrom|
|US9352863||18 sept. 2008||31 mai 2016||Luce Communications Llc||System and method for shipping an item|
|Classification internationale||G01N33/50, G01N33/483, B01L3/00|
|Classification coopérative||G01N33/5091, B01L3/545|
|Classification européenne||B01L3/545, G01N33/50D4|
|8 juin 1995||AK||Designated states|
Kind code of ref document: A1
Designated state(s): AU BR CA JP KP
|8 juin 1995||AL||Designated countries for regional patents|
Kind code of ref document: A1
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
|6 sept. 1995||121||Ep: the epo has been informed by wipo that ep was designated in this application|
|28 août 1996||122||Ep: pct application non-entry in european phase|
|2 sept. 1996||NENP||Non-entry into the national phase in:|
Ref country code: CA